Waddell & Associates, LLC Bristol Myers Squibb CO Transaction History

Waddell & Associates, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $563,580 - $672,506	-11,625 Reduced 62.23%	7,055 $361,000
Q3 2023 Nov 07, 2023	BUY	$57.89 - $64.73 $7,294 - $8,155	126 Added 0.68%	18,680 $1.08 Million
Q2 2023 Aug 07, 2023	SELL	$63.71 - $70.74 $1,019 - $1,131	-16 Reduced 0.09%	18,554 $1.19 Million
Q1 2023 May 10, 2023	BUY	$65.71 - $74.53 $4,993 - $5,664	76 Added 0.41%	18,570 $1.29 Million
Q4 2022 Feb 09, 2023	BUY	$68.48 - $81.09 $6,368 - $7,541	93 Added 0.51%	18,494 $1.33 Million
Q3 2022 Nov 02, 2022	BUY	$0.13 - $76.84 $11 - $6,608	86 Added 0.47%	18,401 $1.31 Million
Q2 2022 Jul 27, 2022	BUY	$72.62 - $79.98 $9,004 - $9,917	124 Added 0.68%	18,315 $1.41 Million
Q1 2022 Apr 21, 2022	BUY	$61.48 - $73.72 $202,453 - $242,759	3,293 Added 22.1%	18,191 $1.33 Million
Q4 2021 Feb 01, 2022	BUY	$53.63 - $62.52 $4,022 - $4,689	75 Added 0.51%	14,898 $929,000
Q3 2021 Nov 10, 2021	BUY	$59.17 - $69.31 $4,615 - $5,406	78 Added 0.53%	14,823 $877,000
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $912,862 - $994,107	14,745 New	14,745 $985,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Waddell & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Waddell & Associates, LLC with notifications on news.